Clinical Trial Update: Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis [Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 2 study evaluating three HU6 dose levels versus placebo in nonalcoholic steatohepatitis; the trial status is ACTIVE_NOT_RECRUI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatty Liver
• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• HU6

Snippet

Sponsor: Rivus Pharmaceuticals, Inc. | Conditions: Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | Status: ACTIVE_NOT_RECRUITING